Printer Friendly

WILLIAM ROHN JOINS IDEC PHARMACEUTICALS AS SENIOR VICE PRESIDENT, COMMERCIAL AND CORPORATE DEVELOPMENT

 SAN DIEGO, Aug. 23 /PRNewswire/ -- IDEC Pharmaceuticals Corp. (NASDAQ: IDPH) today appointed William R. Rohn, 49, to the newly created position of senior vice president, commercial and corporate development. Rohn came to the company from Adria Laboratories, where he served as senior vice president of sales and marketing, and was responsible for strategic and commercial partnerships.
 "Bill Rohn has a wealth of experience in the pharmaceutical industry and in the oncology market, specifically," said William H. Rastetter, Ph.D., president and chief executive officer of IDEC Pharmaceuticals. "At IDEC, he will have primary responsibility for business development, market planning and strategy, and product commercialization and management. Among his initial objectives will be to expand IDEC's corporate alliances with new and existing partners. When our first products become ready for commercialization, he will also lead our sales and marketing efforts. Bill Rohn is an important addition to IDEC's management team, and we're delighted to welcome him aboard."
 At Adria Laboratories since 1985, Rohn directed Adria's day-to-day commercial activities. Prior responsibilities in the company included business development and licensing, as well as management of the oncology products group. He previously held marketing and sales management positions at Abbott Laboratories, Warren-Teed Pharmaceuticals, Miles Laboratories and Mead Johnson Laboratories.
 IDEC Pharmaceuticals is focused on the development of targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company's most advanced product candidates include pan-B antibodies to treat B-cell lymphomas, MELIMMUNE(TM) antibodies to treat malignant melanoma, and a PRIMATIZED(TM) anti-CD4 antibody to treat autoimmune diseases. These agents typically are designed to act through immune system mechanisms and potentially offer greater specificity of action, longer therapeutic effect and lower toxicity than is typical of existing therapies. They also can be administered in outpatient settings, providing the opportunity to reduce overall treatment costs.
 IDEC Pharmaceuticals is located at 11011 Torreyana Road, San Diego, CA 92121.
 -0- 8/23/93
 /CONTACT: Richard W. Krawiec, director of investor relations and corporate communications, or William H. Rastetter, president and CEO, of IDEC Pharmaceuticals, 619-550-8656/
 (IDPH)


CO: IDEC Pharmaceuticals Corp. ST: California IN: MTC SU: PER

JB-JL -- SD001 -- 5031 08/23/93 12:00 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 23, 1993
Words:357
Previous Article:NOBLE DRILLING SIGNS DEFINITIVE PURCHASE AGREEMENT TO PURCHASE NINE JACKUPS; ALSO ANNOUNCES ACQUISITION OF TWO ADDITIONAL OFFSHORE RIGS
Next Article:CENTURA INTRODUCES DEBIT CARD CALLED POCKET CHECK
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters